Haploidentical Bone Marrow and Stem Cell Transplantation: Experience with Post-Transplantation Cyclophosphamide

Allogeneic blood or bone marrow transplantation (BMT) is a potentially curative therapy for high-risk hematologic malignancies not curable by standard chemotherapy, but the procedure is limited by the availability of human leukocyte antigen-matched donors for many patients, as well as toxicities including graft-versus-host disease. Our group has developed the use of high-dose post-transplantation cyclophosphamide (PTCy) to selectively remove alloreactive T cells without compromising engraftment.

Source: Seminars in Hematology - January 15, 2016 Category: Hematology Authors: Tara M. Robinson, Paul V. O’Donnell, Ephraim J. Fuchs, Leo Luznik Source Type: research